Focused On-demand Library for SH3 domain-binding glutamic acid-rich-like protein 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9UJC5

UPID:

SH3L2_HUMAN

Alternative names:

Fovea-associated SH3 domain-binding protein

Alternative UPACC:

Q9UJC5; A8MQU2; Q2VPC2; Q5VV96; Q6NSK8; Q6P9E8; Q7Z734; Q8IWD3; Q9BPY5

Background:

The SH3 domain-binding glutamic acid-rich-like protein 2, also known as Fovea-associated SH3 domain-binding protein, plays a crucial role in cellular processes. Its unique structure, characterized by the SH3 domain, suggests a specific interaction with other proteins, facilitating various cellular functions.

Therapeutic significance:

Understanding the role of SH3 domain-binding glutamic acid-rich-like protein 2 could open doors to potential therapeutic strategies. Its involvement in critical cellular processes makes it a promising target for drug discovery, aiming to modulate its activity for therapeutic benefits.